Targeting senescence to prevent diabetic kidney disease: Exploring molecular mechanisms and potential therapeutic targets for disease management
Diabetic Medicine · 2025-02 · 42 (2)
DOI: 10.1111/dme.15408 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetic Medicine, online erschienen am 12.07.2024. Verfasst von Paige Charlotte Alison Phillips und 5 weiteren Autor:innen. Beteiligte Einrichtung: Joseph Banks Laboratories, College of Health and Science, Lincoln, UK. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Cellular Senescence. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 197 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Aims As a microvascular complication, diabetic kidney disease is the leading cause of chronic kidney disease and end‐stage renal disease worldwide. While the underlying pathophysiology driving transition of diabetic kidney disease to renal failure is yet to be fully understood, recent studies suggest that cellular senescence is central in disease development and progression. Consequently, understanding the molecular mechanisms which initiate and drive senescence in response to the diabetic milieu is crucial in developing targeted therapies that halt progression of renal disease.
Methods
To understand the mechanistic pathways underpinning cellular senescence in the context of diabetic kidney disease, we reviewed the literature using PubMed for English language articles that contained key words related to senescence, inflammation, fibrosis, senescence‐associated secretory phenotype (SASP), autophagy, and diabetes.
Results
Aberrant accumulation of metabolically active senescent cells is a notable event in the progression of diabetic kidney disease. Through autocrine‐ and paracrine‐mediated mechanisms, resident senescent cells potentiate inflammation and fibrosis through increased expression and secretion of pro‐inflammatory cytokines, chemoattractants, recruitment of immune cells, myofibroblast activation, and extracellular matrix remodelling. Compounds that eliminate senescent cells and/or target the SASP – including senolytic and senomorphics drugs – demonstrate promising results in reducing the senescent cell burden and associated pro‐inflammatory effect.
Conclusions
Here we evidence the link between senescence and diabetic kidney disease and highlight underlying molecular mechanisms and potential therapeutic targets that could be exploited to delay disease progression and improve outcomes for individuals with the disease. Trials are now required to translate their therapeutic potential to a clinical setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Joseph Banks Laboratories, College of Health and Science, Lincoln, UK.
Zitieren
APA
Phillips, P. C. A., de Sousa Loreto Aresta Branco, M., Cliff, C. L., Ward, J. K., Squires, P. E., & Hills, C. E. (2025). Targeting senescence to prevent diabetic kidney disease: Exploring molecular mechanisms and potential therapeutic targets for disease management. Diabetic Medicine, 42(2). https://doi.org/10.1111/dme.15408
Vancouver
Phillips PCA, de Sousa Loreto Aresta Branco M, Cliff CL, Ward JK, Squires PE, Hills CE. Targeting senescence to prevent diabetic kidney disease: Exploring molecular mechanisms and potential therapeutic targets for disease management. Diabetic Medicine. 2025;42(2). doi:10.1111/dme.15408
BibTeX
@article{Phillips2025,
author = {Phillips, Paige Charlotte Alison and de Sousa Loreto Aresta Branco, Mafalda and Cliff, Chelsy Louise and Ward, Joanna Kate and Squires, Paul Edward and Hills, Claire Elizabeth},
title = {Targeting senescence to prevent diabetic kidney disease: Exploring molecular mechanisms and potential therapeutic targets for disease management},
journal = {Diabetic Medicine},
year = {2025},
volume = {42},
number = {2},
doi = {10.1111/dme.15408}
}
EUVIMED